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CMR for Sudden Cardiac Death Risk Stratiﬁcation
Are We There Yet?*
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tEach year, up to 400,000 people suffer sudden
cardiac death (SCD) in the United States (1),
mostly due to arrhythmias, namely ventricular
tachycardia (VT) or ventricular fibrillation (VF).
Because survival from out-of-hospital SCD remains
poor, the key to reducing mortality from SCD is
the proper identification of at-risk individuals
before having SCD. Prophylactic implantable
cardioverter-defibrillators (ICDs) have been shown
to improve survival in specific high-risk patient
subgroups. For the primary prevention of SCD in
ischemic or dilated cardiomyopathy, the only non-
invasive risk marker that has been consistently used
in randomized controlled trials to identify patients
who might benefit from ICD therapy is the left
ventricular ejection fraction (LVEF).
See page 335
One of the critical factors predisposing individ-
uals with structural heart disease to life-threatening
ventricular arrhythmias is the presence of substrate.
Although the pathophysiology of VF may be com-
plex, in patients with coronary artery disease
(CAD), the substrate for VT is characterized by an
infarct scar that creates an opportunity for re-entry.
For a number of historical and practical reasons, the
LVEF has become an indirect index of this sub-
strate. Yet, the sensitivity of LVEF for identifying
patients at risk of SCD is limited (1).
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contents of this paper to disclose.Late gadolinium enhanced (LGE) cardiac mag-
etic resonance (CMR) has emerged as a promising
maging technique that can identify the substrate
or VT. LGE-CMR has been shown to accurately
dentify the presence, location, size, and morphol-
gy of myocardial scar. In addition to infarct scar,
GE-CMR can also identify fibrosis resulting from
onischemic mechanisms such as hypertrophic car-
iomyopathy, myocarditis, and dilated cardiomyop-
thy. A growing body of literature demonstrates the
rognostic role of LGE-CMR, independent of
VEF, in patients with and without CAD for the
rediction of cardiovascular endpoints, including
nducibility of VT on electrophysiologic study, ap-
ropriate ICD discharge, and SCD (Table 1).
In this issue of iJACC, Dawson et al. (2) assess
he added benefit of LGE-CMR for the prediction
f subsequent arrhythmic events in patients pre-
enting with VT. Over a 10-year period, 373
atients with a diagnosis of sustained or nonsus-
ained ventricular tachycardia (NSVT) who under-
ent LGE-CMR at a single center were enrolled in
his prospective cohort study and followed for a
edian of 2.6 years for a composite endpoint of
ardiac death, cardiac arrest, sustained VT/VF, or
ppropriate ICD discharge. This study is the first to
nroll patients prospectively on the basis of the
resenting diagnosis of VT, enabling a unique
ssessment of the utility of LGE-CMR in this
atient population. The patients generally had a
reserved LVEF and a relatively low prevalence of
AD. This could reflect referral bias, as physicians
ay have been more likely to order CMR to
valuate patients with VT without apparent struc-
ural heart disease by conventional testing. Multi-
ariable analysis found the presence of LGE to be
he only independent predictor of the composite
ndpoint. In subgroup analysis, LGE and LVEF
STEMI  ST-segment elev tion;
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34635% were both significant predictors in patients
presenting with VT, whereas LGE was the only
significant predictor in those presenting with
NSVT. These findings provide further support for
the added value of fibrosis visualized by LGE-
CMR over LVEF for predicting arrhythmic events.
Although the presence of LGE predicted subse-
quent arrhythmia, a greater extent of LGE did not
appear to confer higher arrhythmic risk. Although
many studies have demonstrated a clear relationship
between the amount of scar and CV risk, others
have not. Klem et al. (3) found a significant step up
in arrhythmic risk when LGE exceeded 5% of LV
volume, but risk plateaued at higher levels. Kwong
he Prognostic Role of LGE-CMR
f. # Population N LVEF (%)
CAD referred for EPS 48 32
No known prior MI, referred for CMR 195 54
CAD with LGE on CMR 144 44
) DCM 101 31
CAD, LVEF 35%, referred for ICD 47 27
CAD s/p STEMI 128 41
CAD, EF 50%, revascularization  ICD 86 26
DCM, LVEF 35% 65 22
Any pt with CMR, excluding
inﬁltrative disease
857 39
CAD 177 45
ICM, getting ICD 91 28
CAD, LVEF 45% 349 24
CAD, EF 50%, revascularization  ICD 70 25
CAD 100 34
(10) CAD, ablation of monomorphic VT 36 32
CAD, getting ICD 64 30
ICM and DCM getting ICD 103 26
) CAD 376 51
ICM and DCM getting EPS  ICD 73 30
ICM and DCM getting ICD 59 26
CAD (53%) and CAD, for EPS  ICD 137 26
Sustained or NSVT 373 60
sease; CMR  cardiac magnetic resonance; CV  cardiovascular; CV hosp  ca
D implantable cardioverter-deﬁbrillator; ICD rx appropriate implantable cardio
ventricular ejection fraction; MI  myocardial infarction; NSVT  nonsustained ve
ation myocardial infarction; VA  ventricular arrhythmia; VF  ventricular ﬁbrillaet al. (4) found a significant increase in risk for eventhe lowest tertile of LGE (mean 1.4%), with a similar
plateau in risk for greater amount of LGE. One expla-
nation for the lack of a clear “dose response” between
LGE and CV risk may be that simple quantification of
scar mass does not tell the entire story.
Characterization of infarct morphology by LGE-
CMR may provide unique insights into the mech-
anism of ventricular arrhythmias beyond what can
be gleaned simply from infarct mass. In a pig model
of chronic myocardial infarction, Ashikaga et al. (5)
demonstrated that the VT isthmus identified by VT
activation patterns using epicardial sock electrodes
corresponded to small areas of viable myocardium
bounded by scar on high-resolution ex vivo
Outcome Finding
Inducible VT Infarct size better predictor
than LVEF
Death, MI, CV hosp,
ICD rx
LGE strongest predictor of
CV events
Mortality Border zone independent predictor
of mortality
Mortality  CV hosp LGE only independent predictor
Inducible VT Gray zone only predictive variable
Death, MI, CV hosp Acute infarct size better predictor
than LVEF
Death, CV hosp,
revascularization, VA
Infarct size was a predictor,
not LVEF
Death, ICD rx, CV hosp LGE only independent predictor
Transplant-free survival Scar index and LVEF are
independent predictors
Mortality  nonfatal MI Spatial scar extent better predictor
than LVEF
Appropriate ICD rx Gray zone only predictive variable
Transplant-free survival Infarct size was a predictor,
not LVEF
Death, CV hosp,
revascularization, VA
Border zone and total scar are
predictive, not LVEF
Mortality Infarct size and LVEF are
independent predictors
VT Heterogeneous tissue channels
more common in VT
Appropriate ICD rx Number of transmural segments
most predictive
ICD rx LGE predictive of ICD rx
Mortality  new-onset HF Infarct size and LVEF are
independent predictors
SCD or ICD discharge Infarct size is an independent
predictor
SCD or ICD discharge Infarct size is an independent
predictor
ICD rx/cardiac death Gray zone predictive
SCD, VT/VF, ICD rx LGE only independent predictor
vascular hospitalization; DCM  nonischemic dilated cardiomyopathy; EPS 
er-deﬁbrillator therapy; ICM ischemic cardiomyopathy; LGE late gadolinium
ular tachycardia; pt  patient; SCD  sudden cardiac death; s/p  status post;
VT  ventricular tachycardia.Table 1. Studies on t
First Author, Year Re
Bello et al., 2005 (13)
Kwong et al., 2006 (4)
Yan et al., 2006 (9)
Assomull et al., 2006 (14
Schmidt et al., 2007 (7)
Wu et al., 2008 (15)
Yokata et al., 2008 (16)
Wu et al., 2008 (17)
Cheong et al., 2009 (18)
Kelle et al., 2009 (19)
Roes et al., 2009 (8)
Kwon et al., 2009 (20)
Heidary et al., 2010 (21)
Bello et al., 2011 (22)
Perez-David et al., 2011
Scott et al., 2011 (23)
Iles et al., 2011 (24)
Catalano et al., 2012 (25
Klem et al., 2012 (3)
Gao et al., 2012 (26)
Wu et al., 2012 (27)
Dawson et al., 2013 (2)
CAD  coronary artery di rdio
electrophysiology study; IC vert
enhancement; LVEF  left ntric3-dimensional (3D) LGE-CMR. Also, in a pig
b
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347model of chronic MI, Ng et al. (6) performed a
“virtual electrophysiology study (EPS)” by assigning
conduction patterns to myocardial voxels on the
basis of signal intensity by 3D LGE-CMR, and
correlated the predicted VT circuits to those ob-
tained from invasive EPS.
Additionally, whereas most studies of LGE-
CMR have focused on the presence and size of scar,
recent studies have attempted to further charac-
terize scar areas by hyperenhancement intensity.
Regions of intermediate-intensity contrast en-
hancement—or “gray zones”—may represent het-
erogeneous zones containing viable and nonviable
myocardium, which are potentially arrhythmogenic.
Increased gray zone mass has been shown to predict
VT inducibility on EPS (7), appropriate ICD
therapy (8), and mortality (9). In patients undergo-
ing EPS for sustained monomorphic VT, Perez-
David et al. (10) found that channels of gray zone
on 3D LGE-CMR corresponded to conduction
channels identified by endocardial voltage mapping.
Given the abundance of single-center studies
demonstrating the prognostic value of LGE-CMR,
are we ready to use this technique to guide ICD
implantation? The American Heart Association has
outlined the recommended phases of evaluation of
novel risk markers of cardiovascular disease (11).
Multiple prospective and retrospective cohort stud-
ies have demonstrated that LGE is predictive of
hard cardiovascular events. Multivariable analyses
have demonstrated the incremental value of LGE-
CMR over established risk markers (LVEF). Ad-
ditionally, reports of improved patient reclassifica-
tion and discrimination are emerging. Dawson et al.
(2) reported a modest, but nonsignificant, improve-
ment in risk stratification on the basis of the net
reclassification index. Klem et al. (3) measured
integrated discrimination improvement and net re-
classification index and demonstrated that incorpo-patients presenting with ventricular patients presenting wtient risk stratification over LVEF and New York
Heart Association functional class.
The definitive phase of evaluation is to test
whether the risk marker improves clinical outcomes
in a randomized clinical trial. One attempt at such
a trial was the DETERMINE (DEfibrillators To
REduce Risk by MagnetIc ResoNance Imaging
Evaluation) trial (12). The DETERMINE trial
sought to test the hypothesis that ICD plus optimal
medical therapy would improve survival over opti-
mal medical therapy alone in patients who were not
candidates for ICDs because of relatively preserved
LVEF, but in whom SCD risk may be increased
due to a large infarct mass by CMR. In this trial,
patients with a history of CAD underwent cine and
LGE-CMR to assess ventricular function and in-
farct mass, respectively. Those with LVEF 35%
and infarct mass 10% of the LV were eligible to
be randomized. Unfortunately, a difficult economic
climate was an impediment to the projected enroll-
ment of 10,000 subjects undergoing LGE-CMR
and 1,500 randomized subjects, and this trial was
stopped after enrolling 655 patients in the registry
and randomizing 81 patients.
Our current ability to risk-stratify patients for
SCD primarily on the basis of LVEF is limited. A
growing body of evidence suggests LGE-CMR
could substantially improve patient selection for
ICD therapy by visualizing the substrate for VT,
infarct scar. As such, LGE-CMR has the potential
to identify patients who will benefit from ICD
therapy despite relatively preserved LVEF, or iden-
tify patients with depressed LVEF who may not
need an ICD. To better serve our patients, the use
of LGE-CMR to guide ICD implantation needs to
be tested in a randomized clinical trial.
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